The prognosis after contraindicated surgery of NSCLC patients with malignant pleural effusion (M1a) may be better than expected

Oncotarget, 2016.

Cited by: 0|Bibtex|Views4|DOI:https://doi.org/10.18632/oncotarget.8566
WOS
Other Links: pubmed.ncbi.nlm.nih.gov|academic.microsoft.com

Abstract:

Although non-small cell lung cancer (NSCLC) with malignant pleural effusion (M1a) is generally contraindicated for surgery, several reports have demonstrated favorable prognosis. This study aimed to describe the results of surgical intervention in this disease. In this retrospective study, we evaluated NSCLC patients with ipsilateral mali...More

Code:

Data:

Your rating :
0

 

Tags
Comments